Equillium (EQ) Gets a Buy Rating from Leerink Partners

In a report issued on March 4, Thomas Smith from Leerink Partners maintained a Buy rating on Equillium (EQResearch Report). The company’s shares closed last Friday at $3.48, close to its 52-week low of $3.35.

According to TipRanks.com, Smith is ranked 0 out of 5 stars with an average return of -22.8% and a 18.5% success rate. Smith covers the Healthcare sector, focusing on stocks such as Connect Biopharma Holdings, Madrigal Pharmaceuticals, and Prometheus Biosciences.

Equillium has an analyst consensus of Strong Buy, with a price target consensus of $12.00.

See the top stocks recommended by analysts >>

The company has a one-year high of $8.70 and a one-year low of $3.35. Currently, Equillium has an average volume of 63.06K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno-inflammatory disorders with high unmet medical need. Its product pipeline include EQ001, is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.

Read More on EQ:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed